Promising cancer treatment modality: The University of California Davis/McClellan Nuclear Radiation Center neutron capture therapy program

Susan Autry-Conwell, James E Boggan, Benjamin Edwards, Yongjin Hou, Graca Vicente, Hungyuan Liu, Wade Richards

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Neutron capture therapy (NCT) is a promising new binary therapeutic modality for the treatment of localized tumors. It is accomplished by injection and localization within the tumor of a neutron capture agent (NCA) that alone, is non-toxic. When the tumor is then exposed to neutrons, a relatively non-toxic form of radiation, cytotoxic products are produced that directly or indirectly cause tumor cell death, and yet preserves normal surrounding tissue not containing the NCA. The UC Davis NCT program is currently working to develop and test new compounds or neutron capture agents (NCA) in vitro and in vivo. Many groups worldwide are also working to develop the next generation NCA, but less than five facilities internationally are currently capable of treating clinical brain tumor patients by NCT and only two U.S. facilities, Massachusetts Institute of Technology (MIT) and Brookhaven National Laboratory (BNL). In addition to compound development, the UC Davis NCT program is preparing the UC Davis McClellan Nuclear Radiation Center's (MNRC) 2 megawatt TRIGA reactor for NCT clinical trials which would make it the only such facility on the West Coast.

Original languageEnglish (US)
Title of host publicationProceedings of SPIE - The International Society for Optical Engineering
PublisherSociety of Photo-Optical Instrumentation Engineers
Pages70-73
Number of pages4
Volume4142
DOIs
StatePublished - 2000
EventPenetrating Radiation Systems and Applications II - San Diego, CA, USA
Duration: Aug 2 2000Aug 3 2000

Other

OtherPenetrating Radiation Systems and Applications II
CitySan Diego, CA, USA
Period8/2/008/3/00

Fingerprint

nuclear radiation
Oncology
therapy
Neutrons
cancer
Radiation
neutrons
Tumors
tumors
Cell death
coasts
death
brain
Coastal zones
Brain
reactors
Tissue
injection

ASJC Scopus subject areas

  • Electrical and Electronic Engineering
  • Condensed Matter Physics

Cite this

Autry-Conwell, S., Boggan, J. E., Edwards, B., Hou, Y., Vicente, G., Liu, H., & Richards, W. (2000). Promising cancer treatment modality: The University of California Davis/McClellan Nuclear Radiation Center neutron capture therapy program. In Proceedings of SPIE - The International Society for Optical Engineering (Vol. 4142, pp. 70-73). Society of Photo-Optical Instrumentation Engineers. https://doi.org/10.1117/12.410584

Promising cancer treatment modality : The University of California Davis/McClellan Nuclear Radiation Center neutron capture therapy program. / Autry-Conwell, Susan; Boggan, James E; Edwards, Benjamin; Hou, Yongjin; Vicente, Graca; Liu, Hungyuan; Richards, Wade.

Proceedings of SPIE - The International Society for Optical Engineering. Vol. 4142 Society of Photo-Optical Instrumentation Engineers, 2000. p. 70-73.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Autry-Conwell, S, Boggan, JE, Edwards, B, Hou, Y, Vicente, G, Liu, H & Richards, W 2000, Promising cancer treatment modality: The University of California Davis/McClellan Nuclear Radiation Center neutron capture therapy program. in Proceedings of SPIE - The International Society for Optical Engineering. vol. 4142, Society of Photo-Optical Instrumentation Engineers, pp. 70-73, Penetrating Radiation Systems and Applications II, San Diego, CA, USA, 8/2/00. https://doi.org/10.1117/12.410584
Autry-Conwell S, Boggan JE, Edwards B, Hou Y, Vicente G, Liu H et al. Promising cancer treatment modality: The University of California Davis/McClellan Nuclear Radiation Center neutron capture therapy program. In Proceedings of SPIE - The International Society for Optical Engineering. Vol. 4142. Society of Photo-Optical Instrumentation Engineers. 2000. p. 70-73 https://doi.org/10.1117/12.410584
Autry-Conwell, Susan ; Boggan, James E ; Edwards, Benjamin ; Hou, Yongjin ; Vicente, Graca ; Liu, Hungyuan ; Richards, Wade. / Promising cancer treatment modality : The University of California Davis/McClellan Nuclear Radiation Center neutron capture therapy program. Proceedings of SPIE - The International Society for Optical Engineering. Vol. 4142 Society of Photo-Optical Instrumentation Engineers, 2000. pp. 70-73
@inproceedings{4be45ce9965b4453a3c196349ac6da84,
title = "Promising cancer treatment modality: The University of California Davis/McClellan Nuclear Radiation Center neutron capture therapy program",
abstract = "Neutron capture therapy (NCT) is a promising new binary therapeutic modality for the treatment of localized tumors. It is accomplished by injection and localization within the tumor of a neutron capture agent (NCA) that alone, is non-toxic. When the tumor is then exposed to neutrons, a relatively non-toxic form of radiation, cytotoxic products are produced that directly or indirectly cause tumor cell death, and yet preserves normal surrounding tissue not containing the NCA. The UC Davis NCT program is currently working to develop and test new compounds or neutron capture agents (NCA) in vitro and in vivo. Many groups worldwide are also working to develop the next generation NCA, but less than five facilities internationally are currently capable of treating clinical brain tumor patients by NCT and only two U.S. facilities, Massachusetts Institute of Technology (MIT) and Brookhaven National Laboratory (BNL). In addition to compound development, the UC Davis NCT program is preparing the UC Davis McClellan Nuclear Radiation Center's (MNRC) 2 megawatt TRIGA reactor for NCT clinical trials which would make it the only such facility on the West Coast.",
author = "Susan Autry-Conwell and Boggan, {James E} and Benjamin Edwards and Yongjin Hou and Graca Vicente and Hungyuan Liu and Wade Richards",
year = "2000",
doi = "10.1117/12.410584",
language = "English (US)",
volume = "4142",
pages = "70--73",
booktitle = "Proceedings of SPIE - The International Society for Optical Engineering",
publisher = "Society of Photo-Optical Instrumentation Engineers",

}

TY - GEN

T1 - Promising cancer treatment modality

T2 - The University of California Davis/McClellan Nuclear Radiation Center neutron capture therapy program

AU - Autry-Conwell, Susan

AU - Boggan, James E

AU - Edwards, Benjamin

AU - Hou, Yongjin

AU - Vicente, Graca

AU - Liu, Hungyuan

AU - Richards, Wade

PY - 2000

Y1 - 2000

N2 - Neutron capture therapy (NCT) is a promising new binary therapeutic modality for the treatment of localized tumors. It is accomplished by injection and localization within the tumor of a neutron capture agent (NCA) that alone, is non-toxic. When the tumor is then exposed to neutrons, a relatively non-toxic form of radiation, cytotoxic products are produced that directly or indirectly cause tumor cell death, and yet preserves normal surrounding tissue not containing the NCA. The UC Davis NCT program is currently working to develop and test new compounds or neutron capture agents (NCA) in vitro and in vivo. Many groups worldwide are also working to develop the next generation NCA, but less than five facilities internationally are currently capable of treating clinical brain tumor patients by NCT and only two U.S. facilities, Massachusetts Institute of Technology (MIT) and Brookhaven National Laboratory (BNL). In addition to compound development, the UC Davis NCT program is preparing the UC Davis McClellan Nuclear Radiation Center's (MNRC) 2 megawatt TRIGA reactor for NCT clinical trials which would make it the only such facility on the West Coast.

AB - Neutron capture therapy (NCT) is a promising new binary therapeutic modality for the treatment of localized tumors. It is accomplished by injection and localization within the tumor of a neutron capture agent (NCA) that alone, is non-toxic. When the tumor is then exposed to neutrons, a relatively non-toxic form of radiation, cytotoxic products are produced that directly or indirectly cause tumor cell death, and yet preserves normal surrounding tissue not containing the NCA. The UC Davis NCT program is currently working to develop and test new compounds or neutron capture agents (NCA) in vitro and in vivo. Many groups worldwide are also working to develop the next generation NCA, but less than five facilities internationally are currently capable of treating clinical brain tumor patients by NCT and only two U.S. facilities, Massachusetts Institute of Technology (MIT) and Brookhaven National Laboratory (BNL). In addition to compound development, the UC Davis NCT program is preparing the UC Davis McClellan Nuclear Radiation Center's (MNRC) 2 megawatt TRIGA reactor for NCT clinical trials which would make it the only such facility on the West Coast.

UR - http://www.scopus.com/inward/record.url?scp=0034467730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034467730&partnerID=8YFLogxK

U2 - 10.1117/12.410584

DO - 10.1117/12.410584

M3 - Conference contribution

AN - SCOPUS:0034467730

VL - 4142

SP - 70

EP - 73

BT - Proceedings of SPIE - The International Society for Optical Engineering

PB - Society of Photo-Optical Instrumentation Engineers

ER -